- Home
- OPP vs FENC Comparison
OPP vs FENC Comparison
Compare OPP & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- FENC
- Stock Information
- Founded
- OPP 2010
- FENC 1996
- Country
- OPP United States
- FENC United States
- Employees
- OPP N/A
- FENC N/A
- Industry
- OPP Finance/Investors Services
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPP Finance
- FENC Health Care
- Exchange
- OPP Nasdaq
- FENC Nasdaq
- Market Cap
- OPP 199.8M
- FENC 229.8M
- IPO Year
- OPP N/A
- FENC 2001
- Fundamental
- Price
- OPP $8.39
- FENC $8.40
- Analyst Decision
- OPP
- FENC Strong Buy
- Analyst Count
- OPP 0
- FENC 2
- Target Price
- OPP N/A
- FENC $13.00
- AVG Volume (30 Days)
- OPP 108.0K
- FENC 79.6K
- Earning Date
- OPP 01-01-0001
- FENC 08-12-2025
- Dividend Yield
- OPP 14.41%
- FENC N/A
- EPS Growth
- OPP N/A
- FENC N/A
- EPS
- OPP N/A
- FENC N/A
- Revenue
- OPP N/A
- FENC $30,912,000.00
- Revenue This Year
- OPP N/A
- FENC $0.85
- Revenue Next Year
- OPP N/A
- FENC $55.16
- P/E Ratio
- OPP N/A
- FENC N/A
- Revenue Growth
- OPP N/A
- FENC N/A
- 52 Week Low
- OPP $7.26
- FENC $3.96
- 52 Week High
- OPP $8.83
- FENC $8.72
- Technical
- Relative Strength Index (RSI)
- OPP 49.88
- FENC 60.82
- Support Level
- OPP $8.32
- FENC $7.53
- Resistance Level
- OPP $8.41
- FENC $8.09
- Average True Range (ATR)
- OPP 0.06
- FENC 0.49
- MACD
- OPP -0.00
- FENC -0.05
- Stochastic Oscillator
- OPP 48.76
- FENC 73.22
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.